Acute anti‐Aβ antibody exposure induces microglial changes and significantly alters chemokine signaling

Abstract INTRODUCTION While the anti‐amyloid‐lowering immunotherapies provide the first disease‐targeting therapies for the treatment of Alzheimer's disease, there remain harmful adverse events causing hesitation among patients, families, physicians, and regulatory bodies. Though these drugs have be...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kate E. Foley, Erica M. Weekman, Donna M. Wilcock
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2026-01-01
Saila:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Gaiak:	anti‐amyloid anti‐Aβ CCL chemokine microglia single‐cell sequencing
Sarrera elektronikoa:	https://doi.org/10.1002/trc2.70201
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!